US Patent Office finally upholds Genentech's "Cabilly II" patent
This article was originally published in Scrip
Executive Summary
Genentech has finally won its fight to protect the "Cabilly II" patent covering the manufacture of monoclonal antibodies. The company says that the US Patent and Trademark Office has finished yet another re-examination and has confirmed the patentability of all of the claims in the patent. Twice before, the PTO has reviewed the patent at the request of third parties and issued a final decision rejecting the patent's claims. Both times, the finding was appealed.